H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter“Fujirebio”) today announced that ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Indian pharma grapples headwinds of US pricing reform & Europe’s HTA-driven cost-effectiveness: Akash Kedia: Nandita Vijayasimha, Bengaluru Monday, June 9, 2025, 08:00 Hrs [IST] ...

Adjusted EPS: $1.31 vs analyst estimates of $1.26 (3.6% beat) ・Adjusted Operating Income: $419 million vs analyst estimates of $409.9 million (25.1% margin, 2.2% beat) ・Revenue Guidance for Q2 CY2025 ...

With rising demand comes new challenges: capacity constraints, shifting regulatory expectations, and the unique requirements of emerging modalities, like cell and gene therapies, are reshaping the ...

The CDMO landscape is changing, influenced by the evolving needs of biotech companies. A notable trend is the growing preference among biotechs for partnering with smaller, more specialized CDMOs.

1.1.10 Current Nucleic Acid Therapeutics CDMO Landscape 1.1.11 Significant Usage of Nucleic Acid Therapeutics 1.1.12 Types of Nucleic Acid Synthesized for Therapeutics 1.1.12.1 Anti-sense ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--#CDMO--Kincell Bio, a leader in cell therapy development and manufacturing, is excited to announce the appointment of Mark R. Bamforth as Chief Executive ...